Arrowhead Pharmaceuticals, Inc.
ARWR US04280A1007
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11% | -42% | -21% | -39% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Hamilton James C SR OFF |
35.00 USD |
20,000 Sold |
700,000 USD |
01/10/2025 | 01/10/2025 |
| Hamilton James C SR OFF |
30.00 USD |
15,000 Sold |
450,000 USD |
12/09/2025 | 12/09/2025 |
| Hamilton James C CMO |
25.00 USD |
15,000 Sold |
375,000 USD |
02/09/2025 | 02/09/2025 |
| Hamilton James C CMO |
20.00 USD |
9,389 Sold |
187,780 USD |
13/08/2025 | 15/08/2025 |
| Hamilton James C CMO |
20.00 USD |
611 Sold |
12,220 USD |
13/08/2025 | 13/08/2025 |
| Anzalone Christopher Richard CEO |
11.49 USD |
50,800 Sold |
583,692 USD |
09/04/2025 | 11/04/2025 |
| Anzalone Christopher Richard CEO |
10.87 USD |
50,000 Sold |
543,500 USD |
09/04/2025 | 10/04/2025 |
| Anzalone Christopher Richard CEO |
11.76 USD |
1,617 Sold |
19,016 USD |
09/04/2025 | 09/04/2025 |
| Anzalone Christopher Richard CEO |
10.75 USD |
3,400 Sold |
36,550 USD |
09/04/2025 | 09/04/2025 |
| Anzalone Christopher Richard CEO |
9.93 USD |
35,305 Sold |
350,579 USD |
09/04/2025 | 09/04/2025 |